Technology Bundle ID
TAB-2753
HIV-1 BED: A Simple Serological Assay for Detecting Recent Infection and Estimating Incidence of Multiple, Worldwide HIV-1 Subtypes
Linked ID
E-555-2013-0
Co-Inventors
Chou-Pong Pau (CDC)
Steve McDougal (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
ICs
CDC
This CDC developed invention is a simple enzyme immunoassay that detects increasing levels of anti-HIV-IgG after seroconversion and can be used for detection of HIV-1 infection. The assay, termed IgG-Capture BED-EIA, incorporates a branched peptide derived from 3 different subtypes to allow equivalent detection of antibodies of different subtypes. The competitive format of the assay allows detection of increasing proportion of HIV-1 IgG for almost 2 years after seroconversion. This is different from what is normally observed in a conventional EIA (with antigen coated plates) that plateaus soon after seroconversion. This assay will be important for HIV prevention activities, targeting resources, and evaluation of ongoing interventions.
Commercial Applications
- HIV clinical serodiagnostics
- Informing clinical decision-making
- Public health/HIV monitoring programs and incidence surveillance
Competitive Advantages
- Ready for commercialization
- Simple and high-throughput capable
- Detects HIV-1 subtypes prevalent in N. America, Europe, Japan, Thailand, Australia, and also central and E. Africa
Request More Info
Licensing Contact: